Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results

Dupilumab is used to treat atopic dermatitis (AD) patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe AD treated with dupilumab in routine clinical practice. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Marron, Servando E., Tomas-Aragones, Lucia, Moncin-Torres, Carlos A., Gomez-Barrera, Manuel, de Aranibar, Francisco Javier Garcia-Latasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305918/
https://www.ncbi.nlm.nih.gov/pubmed/34202315
http://dx.doi.org/10.3390/life11070617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305918/
https://www.ncbi.nlm.nih.gov/pubmed/34202315
http://dx.doi.org/10.3390/life11070617

Ejemplares similares